Interferon B-1a for Clinically Isolated Syndromes

08:00 EDT 7 Sep 2017 | Medscape

This study demonstrates that early initiation of treatment with subcutaneous interferon B-1a following a first clinical demyelinating event significantly delays conversion to multiple sclerosis.
Journal of Neurology, Neurosurgery, and Psychiatry

Original Article: Interferon B-1a for Clinically Isolated Syndromes


More From BioPortfolio on "Interferon B-1a for Clinically Isolated Syndromes"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...